Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
McKinsey
Merck
Express Scripts
Baxter

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR NATRECOR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Natrecor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00075179 ↗ Natrecor in Pulmonary Hypertension Terminated M.D. Anderson Cancer Center Phase 4 2003-12-31 The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.
NCT00083772 ↗ Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated M.D. Anderson Cancer Center Phase 4 2004-05-17 Primary objective is to assess the effect of nesiritide in decreasing left ventricular (LV) filling pressure, defined as pulmonary artery capillary wedge pressure (PCWP) in a group of patients admitted with acute diastolic heart failure. Secondary objectives include: improvement in symptoms, exercise tolerance, improvement in Doppler diastolic filling parameters in patients with diastolic heart failure.
NCT00091520 ↗ A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure Completed Scios, Inc. Phase 2 2004-04-01 The purpose of this study is to evaluate the efficacy and safety of Nesiritide administered as serial infusions to heart failure (HF) patients in the outpatient setting.
NCT00119691 ↗ Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction Completed Scios, Inc. Phase 2 2003-04-01 The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
NCT00119691 ↗ Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction Completed Brigham and Women's Hospital Phase 2 2003-04-01 The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Natrecor

Condition Name

Condition Name for Natrecor
Intervention Trials
Congestive Heart Failure 11
Heart Failure, Congestive 7
Heart Failure 4
Renal Insufficiency 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Natrecor
Intervention Trials
Heart Failure 24
Renal Insufficiency 4
Cardiomyopathies 4
Hypertension 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Natrecor

Trials by Country

Trials by Country for Natrecor
Location Trials
United States 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Natrecor
Location Trials
Minnesota 11
Massachusetts 4
California 3
Illinois 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Natrecor

Clinical Trial Phase

Clinical Trial Phase for Natrecor
Clinical Trial Phase Trials
Phase 4 8
Phase 3 7
Phase 2 7
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Natrecor
Clinical Trial Phase Trials
Completed 20
Terminated 12
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Natrecor

Sponsor Name

Sponsor Name for Natrecor
Sponsor Trials
Scios, Inc. 19
Mayo Clinic 8
National Center for Research Resources (NCRR) 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Natrecor
Sponsor Trials
Other 28
Industry 20
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
Baxter
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.